Indivior Pharmaceuticals, Inc.

Good day and welcome to the conference call and webcast to discuss the merger of Supernas Pharmaceuticals and Indivior Pharmaceuticals. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Peter Vazzo, Investor Relations Representative for Supernus Pharmaceuticals. Please go ahead.

Good morning, everyone, and thank you for joining us to discuss the proposed merger of Supernus Pharmaceuticals and Endivior Pharmaceuticals. A press release announcing the proposed merger was issued earlier this morning. Additionally, this morning, both companies separately reported financial results for the three- and six-month period ending June 30, 2026. As a result of the transaction announcement, Sopranos and Indivior are hosting this joint conference call in lieu of their previously scheduled second quarter 2026 earning calls. Note that today's conference call will focus on the transaction. Before we begin, I'd like to remind everyone that today's discussion regarding Sopernis and Invivior includes forward-looking statements, including expectations regarding the proposed transaction. These statements are subject to risks and certainties, and we encourage you to review the related SEC filings for more detail. For the benefit of those of you who may be listening to the replay, this call is being held and recorded on August 3rd, 2026. Since then, the company may have made additional announcements related to the topics discussed. Now let's turn to slide four. I'm joined on the call today by Jack Attar, President and Chief Executive Officer of Supernus, Joe Ciaffoni, Chief Executive Officer of Indivior, and Tim Deck, Chief Financial Officer of Supernus. Ryan Preblick, Chief Financial Officer of Indivior is also available for Q&A. I will now turn the call over to Jack Attar, President and Chief Executive Officer of Supernus.

Thank you, Peter. Good morning, everyone, and thanks for taking the time to join us on today's call. Let's start with the big picture on slide five. This transaction creates a CNS leader through the combination of two highly complementary businesses. The combined commercial portfolios will total 11 medicines with key growth products anticipated to grow well into the 2030s. The merger provides for four key commercial therapeutic areas in addiction, ADHD, depression, and Parkinson's disease. It also accelerates profitability and cash flow generation with expected annual cost synergies of $125 million, which we expect to realize within the first 12 months following the merger. Our respective teams have spent a great deal of time together identifying and validating these synergies. These synergies are primarily general and administrative redundancies and operational efficiencies that should materialize after the two companies come together. The merger also gives us a strong balance sheet, which enhances our flexibility to pursue future business development and other growth opportunities.